InSysBio announces its participation in 2026 American Conference on Pharmacometrics (ACoP 2026) which is to be held from October 11-14, 2026 at the Gaylord National Resort & Convention Center, Oxon Hill, Maryland, USA. InSysBio team is going to present its QSP modeling services & software to optimize drug development at the Booth #11 and 6 posters, namely:

Monday, October 12, 2026 7:00 AM - 5:00 PM EDT

• (M-088) "Evaluating Combination Dosing Regimens of the Anti-BCMA Antibody-Drug Conjugate Belantamab Mafodotin and Monoclonal Antibody Belantamab in Relapsed or Refractory Multiple Myeloma Using QSP modeling" by Jingqi Q. X. Gong¹, Galina Lebedeva², Alexandra Diakonova², Geraldine Ferron-Brady¹, Oleg Demin², John D. Clements¹

Affiliations: (1) GSK, Upper Providence, PA, USA, (2) InSysBio

• (M-089) "QSP Model of PSMAxCD3 T-cell Engagers Generates Cytokine-based CRS Risk and Efficacy-related Biomarker Predictions to Optimize Clinical Dosing Strategies" by Jingqi Q. X. Gong¹, Tatiana Karelina², Dmitry Shchelokov², Polina Maliukova², Olga Ivanova², Maria Myshkina², Oleg Demin Jr², John Clements¹, Stefan Zajic¹, Murad Melhem³

Affiliations: (1) GSK, Collegeville, PA, USA, (2) InSysBio, (3) GSK, Waltham, MA, USA

Tuesday, October 13, 2026 7:00 AM - 5:00 PM EDT

• (T-038) "SBML-based genome-scale QSP modelling of asthma integrating CYTOCON DB, EHMN2026 with Neural ODEs" by Igor Goryanin^1,3, Oleg Demin², Irina Goryanin³

Affiliations: (1) University of Edinburgh, (2) InSysBio, (3) IQANOVA LTD

• (T-048) "AI-assisted SBML-based QSP modelling of CAR-T therapy: automated model evolution, calibration, and combination therapy evaluation" by Igor Goryanin^1,3, Oleg Demin², Irina Goryanin³

Affiliations: (1) University of Edinburgh, (2) InSysBio, (3) IQANOVA LTD

• (T-113) "Simplified tau pathology model for preclinical efficacy of PROTAC to investigate translation from in vitro protein degradation to in vivo efficacy" by Tatiana Karelina, Marina Morozova

Wednesday, October 14, 2026 7:00 AM - 1:30 PM EDT

• (W-093) "Context-of-Use–Driven Validation of Machine Learning Surrogate Models for Accelerating Virtual Patient Workflows in a QSP Model of Erythropoiesis" by Anna Viktorenko¹, Alexander Stepanov¹, Igor Goryanin², Oleg Demin¹

Affiliations: (1) InSysBio, (2) University of Edinburgh

Check out our posters and Booth #11 at ACoP 2026!

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com

Share